Skip to main content
. Author manuscript; available in PMC: 2017 Aug 17.
Published in final edited form as: NPJ Precis Oncol. 2017 Jun 22;1:23. doi: 10.1038/s41698-017-0026-x

Table 1.

Signaling differences and mutations in tumors that have either mutant p53 or loss of p16ink4a

Mutant p53 Loss of pl6
p42/44 MAPK possible tumor suppressor p42/44 MAPK pro-tumorigenic
Negative for Wilms' Tumor 1 Positive for Wilms' Tumor 1
Ameboid morphology Mesenchymal morphology
Lymph nodes Hematogeneus
Radiation sensitive Radiation resistant
Notch inactivate Notch activation
Survivin Superoxide
graphic file with name nihms894787t1.jpg graphic file with name nihms894787t2.jpg
Stat 3 Stat 3/5
Hif1α Hif2α
Extracellular membrane deposition
Increased telomerase

These represent polar opposites, but in some very advanced tumors, there may be both mutant p53 and loss of p16ink4a, leading to potential signaling plasticity